ImmunoPrecise Antibodies Ltd. Stock Toronto S.E.
Stocks
IPA
CA45257F2008
Pharmaceuticals
| Market Cap | 102M 72.51M 63.37M 58.48M 53.9M 6.98B 104M 699M 275M 3.42B 272M 266M 11.77B | P/E 2026 * |
-6.52x | P/E 2027 * | -7.83x |
|---|---|---|---|---|---|
| Enterprise Value | 102M 72.51M 63.37M 58.48M 53.9M 6.98B 104M 699M 275M 3.42B 272M 266M 11.77B | EV / Sales 2026 * |
6.4x | EV / Sales 2027 * | 4.96x |
| Free-Float |
90.98% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ImmunoPrecise Antibodies Ltd.
| 1 day | +0.78% |
| Manager | Title | Age | Since |
|---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 21/02/2018 |
Richard Areglado
DFI | Director of Finance/CFO | 62 | 20/10/2025 |
Hyfte Van
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Jennifer Bath
BRD | Director/Board Member | - | 24/05/2018 |
Dirk Witters
CHM | Chairman | - | - |
Jonathan Lieber
BRD | Director/Board Member | 56 | 07/07/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.78% | -7.67% | - | - | 72.51M | |
| -0.33% | +1.83% | +24.73% | -6.86% | 68.85B | |
| +0.67% | +0.93% | +36.86% | +197.49% | 52.13B | |
| +0.94% | +39.60% | +39.60% | +39.60% | 43.46B | |
| +1.12% | +0.35% | -52.09% | -53.39% | 41.24B | |
| -1.40% | +3.43% | +64.81% | -25.41% | 30.41B | |
| -2.11% | -9.45% | +97.76% | -49.58% | 24.53B | |
| +0.51% | +0.46% | +72.78% | +90.09% | 23.42B | |
| -5.57% | -0.84% | -0.11% | +182.38% | 19.75B | |
| -0.86% | -1.99% | +70.03% | +117.01% | 16.57B | |
| Average | -0.62% | -0.81% | +39.37% | +54.59% | 35.6B | |
| Weighted average by Cap. | -0.34% | -0.07% | +32.55% | +46.83% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 15.88M 11.33M 9.9M 9.14M 8.42M 1.09B 16.23M 109M 42.96M 534M 42.56M 41.62M 1.84B | 20.47M 14.61M 12.77M 11.78M 10.86M 1.41B 20.92M 141M 55.39M 689M 54.87M 53.67M 2.37B |
| Net income | -14.29M -10.2M -8.91M -8.22M -7.58M -982M -14.61M -98.31M -38.67M -481M -38.3M -37.46M -1.66B | -12M -8.57M -7.49M -6.91M -6.37M -825M -12.27M -82.58M -32.48M -404M -32.18M -31.47M -1.39B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
